For some women, ovarian cancer can become resistant to standard platinum-based chemotherapy
A new phase 3 clinical research study, called the PROCEED study, will evaluate the effectiveness and safety of the investigational drug vintafolide (EC145) in combination with Doxil® for the treatment of women with ovarian cancer whose tumors develop resistance to standard platinum-based chemo-therapy. This research is being conducted by physicians in approximately 160 locations in the US, Canada, and Europe and will include approximately 640 women. Doxil® is known outside the United States as Caelyx®.
All women who choose to participate in the phase 3 clinical study will receive Doxil®, a standard therapy approved for the treatment of patients with platinum-resistant ovarian cancer. Two out of three patients (66%) will also receive the investigational drug vintafolide (EC145).
To participate in the PROCEED study, you must be at least 18 years of age and have platinum-resistant ovarian cancer. Additional eligibility criteria apply; click here to learn more.
For more information about this study, talk to your physician.